Hikma and CanariaBio sign exclusive licensing agreement to bring Oregovomab to the Middle East and North Africa

Main NewsCommunity
By:
On:

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces an exclusive license agreement with CanariaBio, a Korean biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer. Under the terms of the agreement, Hikma has an exclusive license to commercialise Oregovomab in 18Continue Reading

Hikma and CanariaBio sign exclusive licensing agreement to bring Oregovomab to the Middle East and North Africa

Health and Beauty1miscellaneous news
By:
On:

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces an exclusive license agreement with Cassiopea S.p.A., a subsidiary of Cosmo Pharmaceuticals N.V. (Cosmo). Cosmo is focused on developing and commercialising products to treat selected gastrointestinal diseases and dermatological conditions. Under the terms of the agreement, Hikma hasContinue Reading

Hoffmann Green Signs Its First Licensing Agreement in Saudi Arabia With the Shurfah Group

Community
By:
On:

CHAILLÉ-SOUS-LES-ORMEAUX, France — Hoffmann Green Cement Technologies (ISIN: FR0013451044, Mnemo: ALHGR) (Paris:ALHGR) (“Hoffmann Green Cement” or the “Company”), an industrial player committed to the decarbonation of the construction sector that designs and markets innovative clinker-free cements, announces the signature with the Shurfah Group of a 22-year exclusive licensing agreement inContinue Reading

Hikma and Rakuten Medical sign exclusive licensing agreement for AlluminoxTM platform cancer treatment for the Middle East and North Africa

Health and Beauty1
By:
On:

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces an exclusive licensing and commercialisation agreement with Rakuten Medical, Inc. (Rakuten Medical), a global biotechnology company developing and commercialising precision, cell targeting therapies based on its proprietary Alluminox™ platform. Under the terms of the agreement, Hikma hasContinue Reading